Kodiak Sciences Inc

NASDAQ:KODUnited States

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Contact Information

Headquarters

1200 PAGE MILL RDPALO ALTO, CA, United States 94304

Phone

650-281-0850

Fax

302-636-5454

Executives

Chairman of the Board, Chief Executive Officer, Co-Founder

Victor Perlroth

Chief Financial Officer, Executive Vice President, Secretary

John Borgeson

Lead Independent Director

Robert Profusek

Independent Director

Felix Baker

Independent Director

Charles Bancroft